In this study, we found the following: (i) CSAD was significantly decreased in the AF mouse liver along with the decrease in taurine levels, and these decreases were aggravated in Nmnat1-LKO mice; (ii) either hepatic CSAD overexpression or taurine supply robustly reversed Nmnat1-LKO–aggravated lipid accumulation; (iii) Nmnat1-LOE improved the decrease in hepatic CSAD and taurine in ALD. This evidence concerns the gene NMNAT1 and atrial fibrillation.